Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 13 publications below |
| IHC | See 2 publications below |
| IF | See 4 publications below |
Product Information
19797-1-AP targets COL4A5 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | collagen, type IV, alpha 5 |
| Calculated molecular weight | 161 kDa |
| GenBank accession number | NM_000495 |
| Gene Symbol | COL4A5 |
| Gene ID (NCBI) | 1287 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P29400 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
COL4A5 belongs to the type IV collagen family. Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen. Defects in COL4A5 are the cause of Alport syndrome X-linked (APSX). Deletions covering the N-terminal regions of COL4A5 and COL4A6, which are localized in a head-to-head manner, are the cause of diffuse leiomyomatosis with Alport syndrome (DL-ATS)which also known as esophageal and vulval leiomyomatosis with nephropathy or Alport syndrome and diffuse leiomyomatosis (ATS-DL).
Publications
| Species | Application | Title |
|---|---|---|
Biomaterials A novel bioscaffold with naturally-occurring extracellular matrix promotes hepatocyte survival and vessel patency in mouse models of heterologous transplantation. | ||
Int J Mol Med The Notch pathway mediates the angiotensin II-induced synthesis of extracellular matrix components in podocytes. | ||
Pharm Biol Kirenol alleviates diabetic nephropathy via regulating TGF-β/Smads and the NF-κB signal pathway | ||
Am J Physiol Cell Physiol miR-29c Induction Contributes to Down-Regulation of Vascular Extracellular Matrix Proteins by Glucocorticoids. | ||
Front Pharmacol Sappanone a prevents diabetic kidney disease by inhibiting kidney inflammation and fibrosis via the NF-κB signaling pathway |